However, patients with ER+ breast cancer exhibited lower irisin levels compared to ER-breast cancer patients (ER+: 17.84 ± 4.84 ng/ml vs. 19.99 ± 3.69 ng/ml, p=0.04). This evidence concerns the gene FNDC5 and breast cancer.